A Phase Ib/II Study Confirmed Inhibition of Autophagy Synergizes Anti-tumor Effect of High Dose CDK4/6i

NCT05953350 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Inhibition of Autophagy Synergizes Anti-tumor Effect

Interventions

DRUG: 600mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib
DRUG: RP2D dose of 600mg bid of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University